194 related articles for article (PubMed ID: 18533761)
21. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
[TBL] [Abstract][Full Text] [Related]
22. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
23. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
[TBL] [Abstract][Full Text] [Related]
24. Use and safety of antipsychotic drugs during pregnancy.
Einarson A; Boskovic R
J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
Byerly M; Suppes T; Tran QV; Baker RA
J Clin Psychopharmacol; 2007 Dec; 27(6):639-61. PubMed ID: 18004132
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
[No Abstract] [Full Text] [Related]
27. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective.
Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP
Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748
[TBL] [Abstract][Full Text] [Related]
28. The effects of undertreated chronic medical illnesses in patients with severe mental disorders.
Fagiolini A; Goracci A
J Clin Psychiatry; 2009; 70 Suppl 3():22-9. PubMed ID: 19570498
[TBL] [Abstract][Full Text] [Related]
29. Metabolic syndrome - the consequence of lifelong treatment of bipolar affective disorder.
Dadić-Hero E; Ruzić K; Grahovac T; Petranović D; Graovac M; Palijan TZ
Psychiatr Danub; 2010 Jun; 22(2):381-4. PubMed ID: 20562789
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risks of atypical antipsychotic drug treatment.
Drici MD; Priori S
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
[TBL] [Abstract][Full Text] [Related]
31. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C
Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
33. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
34. Metabolic and lifestyle issues and severe mental illness--new connections to well-being?
J Psychopharmacol; 2005 Nov; 19(6 Suppl):188-22. PubMed ID: 19886294
[No Abstract] [Full Text] [Related]
35. Physical health and schizophrenia.
Mitchell AJ; Malone D
Curr Opin Psychiatry; 2006 Jul; 19(4):432-7. PubMed ID: 16721177
[TBL] [Abstract][Full Text] [Related]
36. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
37. Mental disorders and metabolic syndrome: a fatamorgana or warning reality?
Jakovljević M; Crncević Z; Ljubicić D; Babić D; Topić R; Sarić M
Psychiatr Danub; 2007 Jun; 19(1-2):76-86. PubMed ID: 17603420
[TBL] [Abstract][Full Text] [Related]
38. The comorbidity of bipolar disorder and cardiovascular diseases from pharmacotherapy perspective.
Vuksan-Cusa B; Marcinko D; Sagud M; Jakovljević M
Psychiatr Danub; 2009 Sep; 21(3):382-5. PubMed ID: 19794361
[TBL] [Abstract][Full Text] [Related]
39. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics.
Keltner NL
Perspect Psychiatr Care; 2006 Aug; 42(3):204-7. PubMed ID: 16916424
[No Abstract] [Full Text] [Related]
40. Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index.
Laursen TM; Agerbo E; Pedersen CB
J Clin Psychiatry; 2009 Oct; 70(10):1432-8. PubMed ID: 19538905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
